3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
6
Neuroendocrine Tumors
5
Carcinoma, Renal Cell
4
Neoplasm Metastasis
3
Tuberous Sclerosis
2
Triple Negative Breast Neoplasms
2
Recurrence
2
Glioma
2
Endometrial Neoplasms
2
Adenoma, Islet Cell
2
von Hippel-Lindau Disease
1
Vascular Malformations
1
Unilateral Breast Neoplasms
1
Thymus Neoplasms
1
Seizures
1
Sarcoma, Kaposi
1
Sarcoma
1
Nevus
1
Myelodysplastic Syndromes
1
Multiple Endocrine Neoplasia Type 1
1
Metastatic Digestive System Neuroendocrine Tumor G1
1
Meningioma
1
Lymphangioma
1
Liposarcoma
1
Leukemia, Myeloid, Acute
1
Leiomyosarcoma
1
Kidney Neoplasms
1
Hemangioma
1
Hemangioendothelioma
1
Hamartoma Syndrome, Multiple
1
Interventions
Rituximab
9
venetoclax
7
ibrutinib
7
Cyclophosphamide
7
Mycophenolic Acid
5
fludarabine phosphate
4
Whole-Body Irradiation
4
Sirolimus
4
zanubrutinib
3
pirtobrutinib
3
Peripheral Blood Stem Cell Transplantation
3
Dexamethasone
3
Cyclosporine
3
ixazomib
2
fludarabine
2
carfilzomib
2
acalabrutinib
2
Tacrolimus
2
Melphalan
2
Etoposide
2
Cyclosporins
2
Calcium Dobesilate
2
CT-P10
2
Busulfan
2
Bendamustine Hydrochloride
2
talquetamab
1
pembrolizumab
1
loncastuximab tesirine
1
brexucabtagene autoleucel
1
Vincristine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Waldenstrom Macroglobulinemia
×
Everolimus
×
90 days
×
Clear all
No trials found.